Acurx Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.4M
- Price
- $1.48
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.07%
- Volume
- 84.6K
About
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
Quick stats
Shares outstanding4.3M
Computed float3.8M
Float / shares88.4%
Cash runway (months)-1.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001736243
Websitehttps://www.acurxpharma.com
AI Summary
AI-generated1/23
minorbullishregulatory
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
Acurx Pharmaceuticals received FDA conditional acceptance and USPTO trademark allowance for the brand name CIFBEZY for its lead antibiotic candidate ibezapolstat.
These branding milestones support the company's preparation for an international Phase 3 registration program targeting the acute treatment and recurrence reduction of C. difficile infection.
Management noted that trial start-up activities have been initiated for the IBZ-PATHFINDER study, following recent FDA guidance that a single successful Phase 3 trial could support an NDA filing.
Red flags
- Phase 3 advancement is subject to obtaining appropriate financing